Cancer begins when a normal cell accumulates enough genetic or chemical changes to break free of the rules that keep cell division orderly. That breakout is not a single event but a slow, multi-step process in which a cell gradually gains abilities it should not have: growing without permission, ignoring stop signals, dodging the body’s quality-control systems, and eventually traveling to places it does not belong. Understanding how these steps unfold reveals why cancer is so difficult to prevent and treat, and why the disease behaves so differently from one person to the next.
How a Normal Cell Becomes Cancerous
Your body replaces billions of cells every day, and each replacement involves copying roughly three billion letters of DNA. Copying errors are inevitable, but most of them are harmless. The mutations that matter in cancer are called driver mutations: changes that give a cell a concrete growth advantage over its neighbors. A mathematical model of tumor progression describes each new driver mutation as slightly increasing the rate at which that cell’s descendants expand, so the tumor grows in a staircase pattern, one advantage stacked on the next over years or decades.
1PubMed Central. Accumulation of driver and passenger mutations during tumor progressionThe rest of the mutations a tumor accumulates are passengers: they happened to be present in the cell when a driver mutation triggered expansion, so they got copied along for the ride. In one analysis of individual cancer genomes, driver mutations made up a strikingly different share depending on the cancer type, ranging from roughly 17% to 58% of the total point mutations detected.
2PubMed Central. Distinguishing between driver and passenger mutations in individual cancer genomes by network enrichment analysisMutations in the DNA sequence are not the only route. Cells also regulate their genes through chemical tags on DNA and on the protein spools that DNA wraps around. These tags, known as epigenetic marks, can switch genes on or off without changing the underlying code. When epigenetic controls go haywire, a tumor-suppressing gene can be silenced or a growth-promoting gene can be turned up. Disruption of these processes occurs early in tumor development and is considered an essential part of cancer progression.
3PubMed Central. Epigenetic modifications in cancer Genetic mutations can themselves scramble epigenetic patterns, creating a feedback loop where one type of damage amplifies the other.4PubMed Central. Cancer genetics and epigenetics: two sides of the same coin?
Broken Brakes and Stuck Accelerators
Normal cell growth is governed by two broad categories of genes. Growth-promoting genes (oncogenes) are the accelerator, and tumor-suppressor genes are the brake. Cancer typically needs both: an accelerator stuck on and brakes that no longer work.
On the accelerator side, receptor proteins on a cell’s surface normally wait for a specific growth signal before telling the cell to divide. In cancer, these receptors can become permanently active through several routes: a mutation that locks the receptor into an “on” position, extra copies of the receptor gene flooding the surface with too many receptors, chromosomal rearrangements that fuse the receptor to another protein, or the cell producing its own growth signal in a self-stimulating loop.
5PubMed Central. Mechanisms of receptor tyrosine kinase activation in cancer Because these receptors normally regulate growth, movement, and metabolism, their runaway activation pushes the cell toward uncontrolled division.6PubMed Central. Tyrosine kinase – Role and significance in Cancer
On the brake side, two proteins stand out as the cell’s most important guardians: p53 and the retinoblastoma protein (RB). Together, they monitor DNA damage and decide whether a cell should pause to repair itself or stop dividing permanently. Both are inactivated across a wide range of tumor types, which effectively removes the cell’s ability to stop its own division when something goes wrong.
7PubMed Central. Cell cycle regulation: p53-p21-RB signalingHow Cancer Cells Fuel Their Growth
A growing tumor needs raw materials. Healthy cells generate most of their energy through an efficient process in their mitochondria, but cancer cells shift heavily toward a faster but less efficient strategy: they absorb large amounts of glucose and ferment it into lactate, even when oxygen is plentiful and their mitochondria work perfectly fine. This metabolic switch, called the Warburg effect, has puzzled researchers for decades.
8PubMed Central. The Warburg Effect: How Does it Benefit Cancer Cells?The current thinking is that raw energy is not the real bottleneck for a dividing cell. What a cell actually needs to make a copy of itself are building blocks: new DNA letters, new membrane material, new proteins. The Warburg effect, while wasteful in terms of energy per glucose molecule, reroutes carbon from glucose into those building blocks far more effectively than the standard energy pathway does. In other words, cancer cells are not just power-hungry; they are running a construction operation.
9PubMed Central. Understanding the Warburg effect: the metabolic requirements of cell proliferationDodging Death
Cells have a built-in self-destruct program called apoptosis. When DNA damage is severe, or when a cell is behaving abnormally, this program kicks in and dismantles the cell from the inside. Cancer cells adopt various strategies to override apoptosis. Some crank up the production of anti-death proteins that block the self-destruct signal. Others dial down the proteins that trigger it. Many do both simultaneously.
10PubMed Central. Evading apoptosis in cancerNormal cells also have a built-in limit on how many times they can divide, enforced by protective caps on the ends of chromosomes called telomeres. Each division shortens these caps slightly, and eventually the cell can no longer divide. In the large majority of cancer cells, an enzyme called telomerase is reactivated to rebuild those caps, granting the cell essentially unlimited division potential.
11PubMed Central. Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies This maintenance of telomere length is considered critical for the development of what researchers call replicative immortality.12PubMed Central. Integrated evaluation of telomerase activation and telomere maintenance across cancer cell lines
Building a Blood Supply
A tumor cannot grow much beyond a small cluster of cells without its own blood supply. Oxygen and nutrients from existing blood vessels can only diffuse a short distance, so tumors actively recruit new vessels through a process called angiogenesis. The main signal cancer cells use for this is a protein called VEGF. By secreting VEGF, cancer cells coax nearby blood vessels to sprout new branches that grow toward and into the tumor.
13PubMed Central. VEGF signaling: Role in angiogenesis and beyondThe blood vessels that tumors build are abnormal: leaky, disorganized, and poorly structured. This has a paradoxical consequence. While the new vessels deliver enough nutrients to sustain growth, their leakiness also makes it easier for cancer cells to slip into the bloodstream. VEGF’s central role in this process has made it a prominent target for anti-cancer drugs designed to starve tumors of their blood supply.
14PubMed. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGFThe Neighborhood Around the Tumor
Cancer does not grow in isolation. A tumor is surrounded by a complex neighborhood of non-cancerous cells, structural proteins, blood vessels, and immune cells collectively known as the tumor microenvironment. One of the most influential residents of this neighborhood is a type of cell called a cancer-associated fibroblast. In healthy tissue, fibroblasts produce the structural scaffolding that holds organs together. Once co-opted by a tumor, these fibroblasts pump out growth factors, inflammatory signals, and excess scaffolding material that all help the tumor expand.
15PubMed Central. Extracellular Matrices and Cancer-Associated Fibroblasts: Targets for Cancer Diagnosis and Therapy? They also secrete enzymes that chew through the surrounding tissue, clearing a path for tumor cells to invade and helping new blood vessels form.
16PubMed Central. Matrix metalloproteinase (MMP)-9 in cancer-associated fibroblasts (CAFs) is suppressed by omega-3 polyunsaturated fatty acids in vitro and in vivoThe physical stiffness of this scaffolding matters as well. As fibroblasts deposit excess collagen and cross-link it, the tissue around the tumor becomes stiffer. Cancer cells sense that stiffness through surface receptors, and the mechanical signal feeds back to promote more aggressive behavior: increased proliferation, greater invasive ability, and even changes in how well the cells respond to chemotherapy and radiation.
17PubMed Central. Biological role of matrix stiffness in tumor growth and treatmentHiding From the Immune System
The immune system routinely detects and kills abnormal cells. For a tumor to survive, it has to learn to hide. One of the best-understood hiding strategies involves a protein called PD-L1, which many cancer cells display on their surface. PD-L1 binds to a receptor called PD-1 on immune T cells. In healthy tissue, this interaction acts as a “stand down” signal that prevents the immune system from attacking the body’s own cells. Cancer cells hijack this checkpoint to shut down the T cells that would otherwise destroy them.
18PubMed Central. Regulatory mechanisms of PD-1/PD-L1 in cancersThis discovery led directly to a class of drugs called immune checkpoint inhibitors, which block the PD-1/PD-L1 handshake and let the immune system recognize the tumor again. These drugs have produced dramatic responses in some cancers, but many tumors find additional ways to suppress immune activity, which is why the field is still working to understand the full repertoire of evasion tactics.19PubMed. Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape
How Cancer Spreads to Other Organs
Metastasis is the process most responsible for cancer deaths. It requires a cancer cell to break away from the original tumor, enter the bloodstream or lymphatic system, survive the journey, exit at a distant site, and establish a new colony. Each step is a gauntlet, and only a tiny fraction of cells that enter the blood succeed.
The first step usually involves a cellular identity shift. Cells in solid tumors are typically epithelial: tightly packed, anchored to their neighbors. Through a program called the epithelial-mesenchymal transition, some cancer cells shed those anchoring connections, become more mobile, and gain the ability to invade surrounding tissue as individual cells.
20PubMed Central. Epithelial-mesenchymal Transition and Cell Invasion This program also makes cells more resistant to apoptosis, which is useful given the harsh conditions ahead.21PubMed Central. Epithelial-mesenchymal transition in tumor metastasis
Once in the bloodstream, circulating tumor cells face intense physical forces. Blood flow exerts shear stress that destroys most of them. The cells that survive appear to have specific adaptations: one study found that tumor cells respond to fluid shear by expanding their nuclei through a chemical modification of their DNA packaging, and this expansion helps protect them from being torn apart.
22PubMed Central. Fluid shear stress regulates the survival of circulating tumor cells via nuclear expansion Other survival tactics include clumping with platelets or immune cells inside capillaries, which provides a physical shield and can help the tumor cell stick to the vessel wall at a distant site.
23PubMed Central. Mechanobiology and survival strategies of circulating tumor cells: a process towards the invasive and metastatic phenotypeWhy Cancer Spreads to Specific Organs
Metastasis is not random. Breast cancer tends to spread to bone, liver, lung, and brain. Colon cancer favors the liver. Prostate cancer goes to bone. This organ preference, called organotropism, is partly explained by blood-flow patterns, but there is more to it. Research has shown that primary tumors actively prepare distant organs for the arrival of cancer cells, creating what is called a pre-metastatic niche.
Before any cancer cell arrives, the primary tumor releases signals that cause bone-marrow-derived cells to migrate to specific distant sites and modify the local tissue. These early changes include increased production of a structural protein called fibronectin and the accumulation of enzymes that remodel the tissue scaffolding, making the site more hospitable for incoming tumor cells.
24PubMed Central. Preparing the “soil”: the premetastatic niche A more recent framework proposes six defining features of the pre-metastatic niche: immunosuppression, inflammation, new blood vessel growth, lymphatic vessel growth, organ-specific targeting, and metabolic reprogramming of the local tissue.
25PubMed. Characteristics and Significance of the Pre-metastatic NicheOne major way tumors send these long-range instructions is through tiny packages called exosomes. These are small bubbles pinched off from the cell surface that carry proteins, genetic material, and signaling molecules. Tumor-derived exosomes travel through the blood and are taken up by cells at distant sites, reprogramming those cells to create a more welcoming environment. They contribute to vascular remodeling, immune suppression, and the coevolution of the cancer with its future home.
26PubMed Central. Extracellular Vesicles and Metastasis27PubMed Central. Effects of exosomes on pre-metastatic niche formation in tumors
Cancer Stem Cells and Why Tumors Come Back
Not all cells within a tumor are alike. Among the mass of rapidly dividing cells, a small subpopulation behaves differently. These cancer stem cells can renew themselves indefinitely and generate the diverse cell types found within the tumor. They are generally resistant to both chemotherapy and radiation, which means that even when treatment destroys the bulk of the tumor, surviving cancer stem cells can regrow it.
28PubMed Central. Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistanceThis resistance is a major reason cancers relapse. A treatment might shrink a tumor dramatically, but if cancer stem cells survive, they can repopulate the tumor. These cells are also involved in metastatic spread.
29PubMed. Cancer stem cells: Road to therapeutic resistance and strategies to overcome resistance The broader principle at work is tumor heterogeneity. A single tumor is not a uniform mass; it contains many genetically distinct subpopulations, each with different strengths and vulnerabilities. That diversity is the fuel for treatment resistance, because any therapy that kills one subpopulation may leave another unscathed and ready to expand.
30PubMed. Tumour heterogeneity and resistance to cancer therapiesHow Tumors Affect the Whole Body
Cancer is not just a local disease. As tumors grow, they release factors that create bodywide problems. One of the most devastating is cancer cachexia, a wasting syndrome characterized by severe loss of muscle and fat that cannot be reversed by eating more. Tumors release factors that activate a systemic inflammatory response. That inflammation triggers the breakdown of proteins, fats, and carbohydrates throughout the body, as well as hormonal changes including excess cortisol and catecholamine release.
31PubMed Central. Cancer Cachexia: Definition, Staging, and Emerging TreatmentsCachexia affects a large fraction of advanced cancer patients and is directly responsible for a substantial share of cancer deaths. It is not simply starvation: the metabolic changes are driven by signals from the tumor itself, which is why nutritional support alone cannot reverse it. Recognizing cachexia early has become a clinical priority because once it reaches an advanced stage, it is extremely difficult to manage.
Microbes Inside Tumors
A newer area of research has uncovered that tumors are not sterile. Many solid tumors harbor bacteria and other microbes within their own tissue. These intratumoral microbes are not just passive bystanders. Evidence indicates they can promote cancer progression by causing DNA damage, altering epigenetic marks, switching on growth-promoting pathways, and fueling chronic inflammation within the tumor.
32PubMed Central. Emerging roles of intratumoral microbiota: a key to novel cancer therapiesThis discovery has opened the door to an entirely different therapeutic angle: manipulating the microbes inside a tumor to slow its growth or make it more vulnerable to treatment. The field is still young, but it challenges the traditional view that cancer biology is purely a story about the tumor’s own mutated cells.
Why Elephants Rarely Get Cancer
If cancer is fundamentally a numbers game, with every cell division carrying some risk of a dangerous mutation, then larger animals with more cells should get cancer more often. But they do not. This puzzle is called Peto’s Paradox. Animals with roughly a thousand times more cells than humans do not show a correspondingly higher cancer risk, suggesting their cells have evolved suppression mechanisms that are far more effective than ours.
33PubMed Central. Peto’s Paradox: evolution’s prescription for cancer preventionA broad survey of cancer prevalence across mammalian species confirmed this: cancer rates did not increase with body mass or maximum lifespan.
34Evolution, Medicine, and Public Health. Lifetime cancer prevalence and life history traits in mammals Elephants, for example, carry extra copies of the p53 gene, the same tumor suppressor mentioned earlier. Whales have evolved other protective changes in DNA-repair pathways. Studying how large-bodied species solved the cancer problem is an active area of comparative oncology, and it has the potential to suggest new prevention strategies for humans that would not have been discovered by studying human tumors alone.